Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41

作者：

Doebele, R. ^{[1
]}

Ahn, M. ^{[2
]}

Siena, S. ^{[3
,4
]}

Drilon, A. ^{[5
]}

Krebs, M. ^{[6
]}

Lin, C. ^{[7
]}

De Braud, F. ^{[8
]}

John, T. ^{[9
]}

Tan, D. ^{[10
]}

Seto, T. ^{[11
]}

Dziadziuszko, R. ^{[12
]}

Arkenau, H. ^{[13
]}

Barlesi, F. ^{[14
]}

Rolfo, C. ^{[15
]}

Wolf, J. ^{[16
]}

Chow-Maneval, E. ^{[17
]}

Multani, P. ^{[17
]}

Cui, N. ^{[18
]}

Riehl, T. ^{[18
]}

Cho, B. C. ^{[9
]}

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea

[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[4] Univ Milan, Milan, Italy

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA

[6] Univ Manchester, Manchester, Lancs, England

[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan

[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland

[13] Sarah Cannon Res Inst, London, England

[14] Aix Marseille Univ, AP HM, Marseille, France

[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium

[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

[17] Ignyta Inc, San Diego, CA USA

[18] Genentech Inc, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; entrectinib; ROS1 gene fusion;

D O I：

10.1016/j.jtho.2018.08.239

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA02.01

引用

页码：S321 / S322

页数：2